Pancreatic Cancer News and Research RSS Feed - Pancreatic Cancer News and Research

Pancreatic cancer is the fourth leading cause of all cancer deaths in the United States and the third leading cause of cancer deaths in individuals ages 40 to 60. Approximately 37,000 Americans are diagnosed with pancreatic cancer each year, and, each year, approximately the same number die from it. Often, pancreatic cancer is found too late for surgical intervention, and chemotherapy and radiation treatments have little effect.
Drug-resistant E. coli outbreak linked to contaminated endoscopes in Washington state hospital

Drug-resistant E. coli outbreak linked to contaminated endoscopes in Washington state hospital

An outbreak of a novel Escherichia coli (E. coli) strain resistant to antibiotics has been linked to contaminated endoscopes in a Washington state hospital. The study indicates that industry standard cleaning guidelines, which were exceeded by hospital staff, may not be sufficient for sterilizing endoscopes adequately. [More]
Study shows how PDT for pancreatic cancer can be included in physician practice without significant cost

Study shows how PDT for pancreatic cancer can be included in physician practice without significant cost

Late stage pancreatic cancer benefits from photodynamic therapy (PDT) but the resources needed for the usual accompanying dosimetry present barriers, Dartmouth researchers Jonathan T. Elliott, PhD and Brian C. Pogue, PhD have mitigated by using common clinical technologies. [More]
New work flow system may improve patient appointments, reduce time-consuming work

New work flow system may improve patient appointments, reduce time-consuming work

Both patients and physicians may benefit from a "work flow" system developed at military medical facilities and tested at a Johns Hopkins Kimmel Cancer Center clinic, according to results of an efficiency study. [More]
Two American scientists receive Paul Ehrlich and Ludwig Darmstaedter Prize

Two American scientists receive Paul Ehrlich and Ludwig Darmstaedter Prize

Two American scientists, James P. Allison and Carl H. June, will today receive the Paul Ehrlich and Ludwig Darmstaedter Prize in the Paulskirche in Frankfurt. Both give the patient's own immune system the lasting ability to fight cancer, Allison against late stage melanoma, June against leukemia. [More]
Xylem’s YSI biochemistry analyzer is effective tool for cell culture and cancer research

Xylem’s YSI biochemistry analyzer is effective tool for cell culture and cancer research

Specifically for oncology drug development applications, the YSI 2950 biochemistry analyzer is used to measure analytes such as glucose, glutamine, glutamate, lactate, providing a simple, automated analysis of bioprocess cell culture samples, with accurate results in less than a minute. [More]
Unregulated Internet marketing of cancer-related gene tests poses challenges for consumers, physicians

Unregulated Internet marketing of cancer-related gene tests poses challenges for consumers, physicians

Websites that market personalized cancer care services often overemphasize their purported benefits and downplay their limitations, and many sites offer genetic tests whose value for guiding cancer treatment has not been shown to be clinically useful, according to a new study from Dana-Farber Cancer Institute. [More]
Targeting stroma could potentially extend survival of pancreatic cancer patients

Targeting stroma could potentially extend survival of pancreatic cancer patients

Like a stealth jet cloaks itself from radar, cancer cells cloak themselves within tumors by hiding behind a dense layer of cellular material known as stroma. [More]
Researchers report that 15% of pancreatic cancer patients may benefit from personalized therapies

Researchers report that 15% of pancreatic cancer patients may benefit from personalized therapies

Cancer researchers at Indiana University report that about 15 percent of people with pancreatic cancer may benefit from therapy targeting a newly identified gene signature. [More]
Mayo Clinic researchers identify molecule that lays groundwork for development of pancreatic cancer

Mayo Clinic researchers identify molecule that lays groundwork for development of pancreatic cancer

A research team led by investigators from Mayo Clinic's campus in Jacksonville, Florida, and the University of Oslo, Norway, have identified a molecule that pushes normal pancreatic cells to transform their shape, laying the groundwork for development of pancreatic cancer -- one of the most difficult tumors to treat. [More]
CTCA presents research on new cancer nutrition therapies at A.S.P.E.N. Clinical Nutrition Week

CTCA presents research on new cancer nutrition therapies at A.S.P.E.N. Clinical Nutrition Week

Several Cancer Treatment Centers of America clinicians presented research from studies evaluating new cancer nutrition techniques and therapies at the American Society for Parenteral and Enteral Nutrition Clinical Nutrition Week held in Long Beach, Calif., February 14-17, 2015. CTCA clinicians led a plenary session and an oral abstract presentation, and presented eight posters to Clinical Nutrition Week attendees. [More]
Researchers identify molecule that plays key role in aggressive thyroid cancer, other cancers

Researchers identify molecule that plays key role in aggressive thyroid cancer, other cancers

Cancer researchers at Mayo Clinic's campus in Jacksonville, Florida, have identified a molecule they say is important to survival of anaplastic thyroid carcinoma (ATC) — a lethal tumor with no effective therapies. [More]
Oncolytics Biotech’s REOLYSIN receives Orphan Drug Designation for treatment of pancreatic cancer

Oncolytics Biotech’s REOLYSIN receives Orphan Drug Designation for treatment of pancreatic cancer

Oncolytics Biotech® Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY), a clinical-stage biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its lead product candidate, REOLYSIN®, for the treatment of pancreatic cancer. [More]
Combination therapies may overcome resistance to targeted cancer drugs

Combination therapies may overcome resistance to targeted cancer drugs

A protein called YAP, which drives the growth of organs during development and regulates their size in adulthood, plays a key role in the emergence of resistance to targeted cancer therapies, according to a new study led by UC San Francisco researchers. [More]
41% of the British population unaware of the role of diet in cancer development

41% of the British population unaware of the role of diet in cancer development

Surprising new statistics reveal that 41% of the British population are oblivious to the role that diet plays in the development of cancer - and even those with a family history of the disease are failing to consume potentially "cancer-preventing" compounds in their daily diet. [More]
Chinese researchers achieve major breakthrough in nano-carrier drugs for pancreatic cancer

Chinese researchers achieve major breakthrough in nano-carrier drugs for pancreatic cancer

At the "Symposium on the Application of Genetic Testing in Individualized Diagnosis and Treatment of Tumor" recently held in Tianjin, the research team led by Professor Hao Jihui of the Pancreas Oncology Department of Tianjin Medical University Cancer Hospital announced that they had achieved a major breakthrough in the field of nano-carrier drugs for pancreatic cancer. [More]
Researchers devise new technique to deliver cancer treatment

Researchers devise new technique to deliver cancer treatment

A team of researchers has devised a new way to target tumors with cancer-fighting drugs, a discovery that may lead to clinical treatments for cancer patients. [More]
Research findings demonstrate new approach to transform behavior of tumor cells

Research findings demonstrate new approach to transform behavior of tumor cells

Inserting a specific strain of bacteria into the microenvironment of aggressive ovarian cancer transforms the behavior of tumor cells from suppression to immunostimulation, researchers at Norris Cotton Cancer Center and the Geisel School of Medicine at Dartmouth have found. [More]
Researchers are one step closer to devising an approach to identify pancreatic cancer earlier

Researchers are one step closer to devising an approach to identify pancreatic cancer earlier

Pancreatic cancer affects approximately 46,000 people each year in the United States and ranks fourth among the leading causes of cancer-related deaths. Only about 6 percent of individuals with pancreatic cancer will live five years after their diagnosis. [More]

Pancreatic Cancer Action Network praises President Obama for new Precision Medicine Initiative

"The Pancreatic Cancer Action Network applauds President Obama for his new Precision Medicine Initiative, and for making an important investment to advance cancer research and arm the scientific and medical community with the cutting edge tools and resources needed to fight cancer. This is especially welcome news for patients fighting pancreatic cancer who face a five-year survival rate of just seven percent. [More]
Pancreatic cancer cells know a way to sidestep chemotherapy, reveal Fox Chase researchers

Pancreatic cancer cells know a way to sidestep chemotherapy, reveal Fox Chase researchers

Pancreatic cancer is one of the deadliest forms of the disease. The American Cancer Society's most recent estimates for 2014 show that over 46,000 people will be diagnosed with pancreatic cancer and more than 39,000 will die from it. Now, research led by Timothy J. Yen, PhD, Professor at Fox Chase Cancer Center, reveals that one reason this deadly form of cancer can be so challenging to treat is because its cells have found a way to sidestep chemotherapy. [More]
Advertisement
Advertisement